Basiliximab reduces acute liver allograft rejection in pediatric patients.
Strassburg
A
A
Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Children's Hospital, Hannover Medical School, Hannover, Germany.
Pfister
E D
ED
Arning
A
A
Nashan
B
B
Ehrich
J H H
JH
Melter
M
M
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D008107:Liver Diseases / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D016559:Tacrolimus